CML facts Flashcards
Nilotinib SE
CV
Metabolic syndrome
Pancreatic enzymes/Pnacreatitis
Hyperbilirubinemia
QT prolongation
Nilotinib 1st line in CML
ENESTnd
Dasatinib 1st line in CML
DASISON
Bosutinib 1st line in CML
BEFORE
Dasatinib dose
100 mg qd
Nilotinib dose
300 mg bid
without food
Bosutinib dose
400 mg qd
start gradually
ramp up of 200 for 1-2 weeks
300 for 1-2 weeks
Imatinib trial in CML
IRIS
Imatinib dose
400 mg qd
Imatinib SE
Neutropenia
Fatigue
GI
Rash
Edema
Muscle cramps
Goals of Tx in CML
OS
Minimal damage to QOL
Decrease risk of long term toxicity
DMR to allow TFR
Dasatinib SE
Neutropenia
Thrombocytopenia and platelet dysfunction
PHTN
Pleural effusion
Dasatinib 2nd line in CML
START-R
Phase II
Imatinib resistant
Compared to high dose imatinib
Deeper and longer responses
Ponatinib 2nd/3rd line in CML
PACE
phase II
Long term OS 70%
30% ATE
Ponatinib 1st line in CML
EPIC- negative trial due to toxicity
Ponatinib SE
CV- 26%
Thrombocytopenia
Rash
Dry skin
Abdominal pain